Alan Raffensperger has joined Swedish Orphan Biovitrum (Sobi) as chief operating officer with responsibility for sales & marketing, supply chain, procurement and IT.
Most recently he was chief executive of Benechill, a US medical device company within the hypothermia therapeutic field. From 2005–2010 he was employed by Amgen and served as executive director, Head of Nephrology from 2008–2010 based at the international headquarters in Switzerland, and general manager of the Nordic and Baltic region 2005–2008, based in Sweden.
Raffensperger was sales and marketing director at Roche Pharmaceuticals, Sweden 1999–2004; vice president, Global Marketing Diabetes Care at Roche Diagnostics 1996–1998 based in Germany, and business director Europe, Diabetes Care at Boeringher Mannheim 1994–1996, also based in Germany. He has also held leading positions within Pharmacia in Sweden and the US.
Sobi is an integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. Its product portfolio consists of around 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are inflammation and genetics and metabolism.
Sobi appoints chief operating officer
Alan Raffensperger takes over sales & marketing, supply chain, procurement and IT
You may also like
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA